Human Health Biotechnology: Can Brazil Advance?
Requires Subscription or Fee PDF

Keywords

biotechnology
innovation
research and development
economic growth.

Abstract

The Brazilian human health biotechnology sector was analyzed according to its spacial and sectorial distribution of the following aspects: (i) the scientific production; (ii) dependence of companies on governmental funding for research and development; (iii) the lack of innovative capacity regarding the discovery and development of new drugs and (iv) a disconnection between the advancement of scientific output and innovation within the private sector. The picture depicted suggests that, despite the advances being made in science and technology, it is still necessary to overcome many weaknesses to achieve an economic growth based on knowledge and innovation.

https://doi.org/10.5912/jcb670
Requires Subscription or Fee PDF

References

Capes, “GEOCAPES - coordenação de aperfeiçoamento de pessoal de nível superior†http://geocapes.capes.gov.br/geocapesds/, accessed January 2013.

Hollanders, H. and Soete, L. (2010) “O crescente papel do conhecimento na economia globalâ€. In: Relatório UNESCO report about science 2010. Translation by Demerval de Sena Aires Júnior. Sector of Natural Sciences, Unesco Brazil.

MCTI, “Indicadores - Ministério da Ciência, Tecnologia e Inovaçãoâ€, http://www.mct.gov.br, accessed in 01/2013.

Gadelha, Carlos Augusto, Costa, Laís Silveira e Maldonado, José. “O complexo econômico-industrial da saúde e a dimensão social e econômica do desenvolvimentoâ€. Revista Saúde Pública, vol. 46, supl. 1, São Paulo: USP, dez. 2012.

SIR world report 2012: global ranking.

Preliminary data published by SCImago journal & country rank (2012) that were included in the documents that could be quoted ("Citable documents").

Cruz, Carlos Henrique de Brito e Chaimovich, Hernan. (2010) “Brasilâ€. In: Relatório UNESCO sobre ciência 2010. Translation by Demerval de Sena Aires Júnior. Sector of Natural Sciences, Unesco Brazil.

Fapesp (2011). “Indicadores de CT&I em saúde no estado de São Pauloâ€. In: Indicadores de ciência, tecnologia e inovação em São Paulo 2010, São Paulo.

Fapesp (2011). “Atividade de patenteamento no Brasil e no exteriorâ€. In: Indicadores de ciência, tecnologia e inovação em São Paulo 2010, São Paulo.

http://download.finep.gov.br/programas/inovar/Resultados.pdf, accessed on 03/02/2014.

Huggett, B. (2013) Public biotech 2012 – the numbers. Nature biotechnology 31(8): 697–703.

Gadelha, Carlos Augusto. “Desenvolvimento, complexo industrial da saúde e política industrialâ€. Revista Saúde Pública, n. 40, São Paulo: USP, 2006, pp. 11-23.

Gadelha, Carlos Augusto, Quental, Cristiane e Fialho, Beatriz de Castro. “Saúde e inovação: uma abordagem sistêmica das indústrias da saúdeâ€. Cad. Saúde Pública, Rio de Janeiro, 19(1), jan.-fev., 2003, pp. 47-59. Fapesp. “Indicadores de CT&I em saúde no estado de São Pauloâ€. In: Indicadores de ciência, tecnologia e inovação em São Paulo 2010. São Paulo: Fapesp, 2011.

Rezaie, R., Frew S.E., Sammut, S.M., Maliakkal, M.R., Daar, A.S. and Singer P.A. (2008). Brazilian health biotech – fostering crosstalk between public and private sectors. Nature Biotechnology 26: 627-644.

Shadlen, Kenneth e Fonseca, Elize Massard. “Health Policy as Industrial Policy: Brazil in Comparative Perspectiveâ€. Politics & Society. London: sage Publications, v. 41, n. 4, p. 561‑587, 2013.

Costa, Laís Silveira, Gadelha, Carlos Augusto e Metten, Antoine. “Saúde e desenvolvimento no Brasil: estado da arte e desafiosâ€. In: Jornada nacional de economia da saúde, 6ª edição, Brasília, 2012.

Ministério da Saúde, 2013: http://www.brasil.gov.br/saude/2013/12/brasil-vai-desenvolver-19-novos-produtos-de-saude, accessed on 12/12/2013.

http://www.planalto.gov.br/ccivil_03/_Ato2011-2014/2012/Decreto/D7713.htm

Schmidt, M.I, Duncan, B.B., Azevedo e Silva, G., Menezes, A.M. Monteiro, C.A., Barreto, S.M., Chor, D. And Menezes, P.R. (2011) Chronic non-communicable diseases in Brazil. The Lancet 377:1949-1961.

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.